Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.23.2
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 17, 2023
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   $ 651,005 $ 416,710 $ 1,256,849 $ 805,703  
Research and development expenses   903,243 2,077,499 1,498,519 3,178,898  
Prepaid Expense and Other Assets, Current   1,319,035   1,319,035   $ 556,094
Prepaid expenses and other   37,000   37,000    
Revenues   651,005 416,710 1,256,849 805,703  
Collaborative Agreements [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenues   0 0 0 0  
Takeda [Member] | Royalty Revenue [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenue   700,000 $ 400,000 1,300,000 $ 800,000  
Catalent Pharma Solutions [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       1,800,000    
Prepaid Expense and Other Assets, Current   $ 900,000   900,000   $ 300,000
Scripps Research [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses $ 938,000          
Initial payment for research 78,000          
Monthly payment $ 78,000          
Scripps Research [Member] | Scripps Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       $ 300,000